AstraZeneca is Waiting to be Found by Investors

3/21 - "AstraZeneca plc (ADR) (Public, NYSE:AZN) the U.K.'s second-largest drugmaker is just $2 away from their 52-week low yet they have 10 drugs in Phase 3 Trials and their lineup of 12 drugs rake in more than $1 billion a year in revenue...The stock has been beat down because AstraZeneca needs new products to boost revenue as generic drugmakers threaten sales of some of its biggest medicines. They have three lawsuits pending against companies seeking to sell copies of ulcer treatment Nexium, its best- selling product."

"AstraZeneca's pipeline is huge, just take a look at their website and if they manage to get a drug or two approved and some positive press, it's game on for AZN shares. Pharma stocks are a tough call during these turbulent times and if it's not for you, then pass. But do keep AZN on your watch list, there's plenty of time to get in on this stock and with the way things are going, shares could fall right back under $35."